Innate Pharma S.A.
IPHYF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$49,471 | -$7,570 | -$58,103 | -$52,809 |
| Dep. & Amort. | $1,994 | $5,091 | $45,405 | $4,596 |
| Deferred Tax | $0 | $0 | $1,664 | -$1,682 |
| Stock-Based Comp. | $3,944 | $4,256 | $4,249 | $2,617 |
| Change in WC | $39,162 | -$32,091 | -$12,502 | -$9,884 |
| Other Non-Cash | -$2,525 | -$2,244 | $133 | -$1,295 |
| Operating Cash Flow | -$6,896 | -$32,558 | -$19,154 | -$58,457 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$391 | -$351 | -$1,122 | -$1,330 |
| Net Acquisitions | $0 | $150 | $0 | $7 |
| Inv. Purchases | $0 | $1 | $0 | $0 |
| Inv. Sales/Matur. | $9,590 | $22,768 | $3,000 | $0 |
| Other Inv. Act. | $1 | -$1,937 | -$1 | $406 |
| Investing Cash Flow | $9,200 | $20,631 | $1,877 | -$917 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$8,936 | -$2,361 | -$2,026 | $26,631 |
| Stock Issued | $0 | $395 | $198 | $499 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $2,928 | $395 | $198 | $187 |
| Financing Cash Flow | -$6,008 | -$1,966 | -$1,828 | $26,818 |
| Forex Effect | -$505 | $274 | -$428 | -$483 |
| Net Chg. in Cash | -$4,209 | -$13,620 | -$19,531 | -$33,036 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $70,605 | $84,225 | $103,756 | $136,792 |
| End Cash | $66,396 | $70,605 | $84,225 | $103,756 |
| Free Cash Flow | -$7,287 | -$34,909 | -$20,276 | -$59,787 |